Loading...
XNASCRVS
Market cap334mUSD
Dec 27, Last price  
5.21USD
1D
-1.51%
1Q
1.17%
Jan 2017
-63.57%
IPO
-63.44%
Name

Corvus Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:CRVS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.79%
Rev. gr., 5y
%
Revenues
0k
Net income
-27m
L-45.99%
-175,636-31,335,000-36,375,000-55,663,000-46,939,000-43,747,000-4,823,000-38,200,000-50,049,000-27,029,000
CFO
-24m
L-11.43%
-104,727-11,328,000-27,857,000-46,212,000-40,988,000-37,321,000-34,778,000-36,715,000-27,023,000-23,935,000
Earnings
Mar 17, 2025

Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
URL
https://www.corvuspharma.com/
IPO date
Mar 23, 2016
Employees
29
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
23,558
32,932
39,090
Unusual Expense (Income)
NOPBT
(23,558)
(32,932)
(39,090)
NOPBT Margin
Operating Taxes
8,742
(5,041)
Tax Rate
NOPAT
(23,558)
(41,674)
(34,049)
Net income
(27,029)
-45.99%
(50,049)
31.02%
(38,200)
692.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,843
62,158
BB yield
-9.28%
-61.62%
Debt
Debt current
2,748
2,601
3,647
Long-term debt
1,374
3,974
6,248
Deferred revenue
Other long-term liabilities
(2,601)
Net debt
(39,150)
(57,605)
(93,822)
Cash flow
Cash from operating activities
(23,935)
(27,023)
(36,715)
CAPEX
(34)
(269)
(5)
Cash from investing activities
15,541
(23,276)
21,560
Cash from financing activities
7,855
62,158
FCF
(22,726)
(40,701)
(35,591)
Balance
Cash
27,149
42,303
69,451
Long term investments
16,123
21,877
34,266
Excess cash
43,272
64,180
103,717
Stockholders' equity
(335,679)
(308,246)
(264,507)
Invested Capital
377,111
366,962
365,316
ROIC
ROCE
EV
Common stock shares outstanding
48,025
46,554
41,854
Price
1.76
107.06%
0.85
-64.73%
2.41
-32.30%
Market cap
84,524
113.60%
39,570
-60.77%
100,868
-3.88%
EV
45,374
(18,035)
7,046
EBITDA
(23,407)
(32,565)
(38,630)
EV/EBITDA
0.55
Interest
1,584
654
15
Interest/NOPBT